Robert Luckett, MD
Gastroenterology · New Albany, INNPI 1972999050
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,000 of the $61,482 with a category attached, or 69.9%. Phathom Pharmaceuticals, Inc. accounts for 91.9% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $40,054, more than ten times the $112 reported in 2019. Among gastroenterology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 367 payments — averaging $167.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$56K
- AbbVie$1K
- Johnson & Johnson$618
- Takeda Pharmaceuticals U.S.A., Inc.$549
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$517
- Sanofi$219
- plus $2K from 27 others
Across 6 payments — averaging $21,847 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$131K
What the payments were for
- Speaking & faculty fees$43,00070%
- Travel & lodging$12,01020%
- Food & beverage$6,26310%
- Education$2080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 87 | $56,485 |
| AbbVie | 73 | $1,229 |
| Johnson & Johnson(2 entities) | 24 | $618 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $549 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 36 | $517 |
| Sanofi | 12 | $219 |
| Pfizer | 13 | $208 |
| Gilead | 9 | $172 |
| Ardelyx, Inc. | 9 | $168 |
| Merck | 9 | $156 |
| Regeneron Healthcare Solutions, Inc. | 6 | $138 |
| Bristol Myers Squibb | 7 | $120 |
| Endogastric Solutions, Inc | 2 | $111 |
| QOL Medical, LLC | 5 | $108 |
| Intercept Pharmaceuticals, Inc. | 6 | $104 |
| Daiichi Sankyo Inc. | 4 | $70 |
| Ironwood Pharmaceuticals, Inc | 3 | $55 |
| Alnylam Pharmaceuticals Inc. | 3 | $52 |
| Amgen | 3 | $48 |
| Janssen Scientific Affairs, LLC | 2 | $48 |
| Organon | 5 | $47 |
| Tersera Therapeutics LLC | 2 | $45 |
| Madrigal Pharmaceuticals | 2 | $42 |
| Fresenius Kabi USA, LLC | 2 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Celltrion USA Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Sandoz | 1 | $13 |
| CSL Behring | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,482 in reported general payments places this provider in the 95th percentile of 323 gastroenterology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi On-BodyRisankizumab-Rzaa | 19 | $417,225 |
| LinzessLinaclotide | 52 | $62,443 |
| CreonLipase/Protease/Amylase | 19 | $60,820 |
| XifaxanRifaximin | 11 | $36,204 |
| ZenpepLipase/Protease/Amylase | 14 | $23,689 |
| MotegrityPrucalopride Succinate | 21 | $14,409 |
| VoqueznaVonoprazan Fumarate | 16 | $10,637 |
| Mesalamine | 18 | $9,462 |
| Pantoprazole Sodium | 201 | $3,197 |
| Colestipol Hcl | 37 | $2,813 |
| Lubiprostone | 25 | $2,642 |
| Omeprazole | 209 | $1,876 |
| Famotidine | 145 | $1,527 |
| Lactulose | 17 | $1,264 |
| Ursodiol | 14 | $1,177 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $1,229 | $123,26371 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $517 | $36,20411 claims |
| Aimmune Therapeutics, Inc.Zenpep | $20 | $23,68914 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $549 | $14,40921 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $56,485 | $10,63716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 323 gastroenterology providers in Indiana.
Other gastroenterology in New Albany
- Jonathan ObertNew Albany$302K
- Steven HarrellNew Albany$12K
- Abdul JabbarNew Albany$9K
- Douglas RexIndianapolis$557K
- Ajay JainIndianapolis$432K
- Monika FischerIndianapolis$258K
- Naga ChalasaniIndianapolis$255K
- Matthew BohmWestfield$239K
- Thomas ImperialeIndianapolis$188K
- Mark GromskiIndianapolis$154K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.